Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) traded up 3.5% during mid-day trading on Monday . The stock traded as high as $64.64 and last traded at $64.36, with a volume of 313,280 shares. The stock had previously closed at $62.18.

Several equities research analysts have issued reports on the stock. Zacks Investment Research raised shares of Alnylam Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, April 25th. Piper Jaffray Cos. reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, May 26th. Jefferies Group reaffirmed a “buy” rating and set a $80.00 price target (down from $119.00) on shares of Alnylam Pharmaceuticals in a research note on Wednesday, June 8th. Chardan Capital reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, April 14th. Finally, Cowen and Company reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Sunday, April 17th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $117.82.

The stock’s market cap is $5.43 billion. The stock’s 50 day moving average price is $61.70 and its 200-day moving average price is $65.95.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Monday, May 2nd. The biopharmaceutical company reported ($1.21) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.05) by $0.16. During the same quarter in the prior year, the company earned ($0.62) earnings per share. The company earned $7.30 million during the quarter, compared to analysts’ expectations of $7.79 million. The company’s quarterly revenue was down 60.4% compared to the same quarter last year. Equities research analysts forecast that Alnylam Pharmaceuticals Inc. will post ($4.94) EPS for the current fiscal year.

In related news, CEO John Maraganore sold 30,151 shares of Alnylam Pharmaceuticals stock in a transaction dated Wednesday, April 20th. The stock was sold at an average price of $67.46, for a total value of $2,033,986.46. Following the transaction, the chief executive officer now owns 148,465 shares of the company’s stock, valued at approximately $10,015,448.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

A number of institutional investors recently modified their holdings of ALNY. Kornitzer Capital Management Inc. KS boosted its position in shares of Alnylam Pharmaceuticals by 62.8% in the fourth quarter. Kornitzer Capital Management Inc. KS now owns 91,150 shares of the biopharmaceutical company’s stock worth $8,581,000 after buying an additional 35,150 shares in the last quarter. Sei Investments Co. boosted its position in Alnylam Pharmaceuticals by 493.7% in the fourth quarter. Sei Investments Co. now owns 19,569 shares of the biopharmaceutical company’s stock valued at $1,842,000 after buying an additional 16,273 shares during the period. Swiss National Bank boosted its position in Alnylam Pharmaceuticals by 2.5% in the fourth quarter. Swiss National Bank now owns 138,300 shares of the biopharmaceutical company’s stock valued at $13,020,000 after buying an additional 3,400 shares during the period. Nationwide Fund Advisors boosted its position in Alnylam Pharmaceuticals by 18.3% in the fourth quarter. Nationwide Fund Advisors now owns 56,508 shares of the biopharmaceutical company’s stock valued at $5,320,000 after buying an additional 8,742 shares during the period. Finally, Baillie Gifford & Co. boosted its position in Alnylam Pharmaceuticals by 284.6% in the fourth quarter. Baillie Gifford & Co. now owns 2,727,734 shares of the biopharmaceutical company’s stock valued at $256,790,000 after buying an additional 2,018,484 shares during the period.

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.